{"id":383245,"date":"2020-11-17T11:41:49","date_gmt":"2020-11-17T16:41:49","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383245"},"modified":"2020-11-17T11:41:49","modified_gmt":"2020-11-17T16:41:49","slug":"chief-executive-officer-patrik-dahlen-buys-immunovia-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/","title":{"rendered":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LUND, Sweden<\/span>, Nov. 17, 2020<\/span> \/PRNewswire\/ — Immunovia\u00a0AB (publ) (“Immunovia”) announced today that Immunovia’s Chief Executive Officer, Patrik Dahlen<\/span>, has acquired Immunovia 15,000 shares for 2.5 MSEK on the open market and his total holding is now 45,000 shares.<\/p>\n

\n For more information, please contact:<\/b>\n <\/p>\n

\n Julie Silber<\/span>, Director of Investor Relations, Immunovia<\/p>\n

Email:\u00a0julie.silber@immunovia.com<\/a><\/p>\n

Tel: +46 7 93 486\u00a0277<\/p>\n

\n The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET<\/span> on November 17, 2020<\/span>.<\/i>\n <\/p>\n

\n About Immunovia<\/b>
\n
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.<\/p>\n

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund<\/span> University and CREATE Health Cancer Center, Sweden<\/span>.<\/p>\n

The first product, IMMray\u2122 PanCan-d, is undergoing clinical evaluation in some of the\u00a0world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1<\/a>\u00a0and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2. <\/p>\n

When validated, IMMray\u2122 PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.<\/p>\n

\n Immunovia Dx Laboratories located in Marlborough, Massachusetts<\/span>, USA and Lund, Sweden<\/span> will provide laboratory testing services in two accredited reference laboratories. <\/i>\n <\/p>\n

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/immunovia-ab\/r\/chief-executive-officer–patrik-dahlen-buys-immunovia-shares,c3238889<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/13121\/3238889\/1336345.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Release<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares-301175081.html<\/a><\/p>\n

SOURCE Immunovia AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LUND, Sweden, Nov. 17, 2020 \/PRNewswire\/ — Immunovia\u00a0AB (publ) (“Immunovia”) announced today that Immunovia’s Chief Executive Officer, Patrik Dahlen, has acquired Immunovia 15,000 shares for 2.5 MSEK on the open market and his total holding is now 45,000 shares. For more information, please contact: Julie Silber, Director of Investor Relations, Immunovia Email:\u00a0julie.silber@immunovia.com Tel: +46 7 93 486\u00a0277 The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET on November 17, 2020. About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker … <\/p>\n

Continue reading “Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383245","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nChief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Nov. 17, 2020 \/PRNewswire\/ — Immunovia\u00a0AB (publ) (“Immunovia”) announced today that Immunovia’s Chief Executive Officer, Patrik Dahlen, has acquired Immunovia 15,000 shares for 2.5 MSEK on the open market and his total holding is now 45,000 shares. For more information, please contact: Julie Silber, Director of Investor Relations, Immunovia Email:\u00a0julie.silber@immunovia.com Tel: +46 7 93 486\u00a0277 The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET on November 17, 2020. About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker … Continue reading "Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T16:41:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares\",\"datePublished\":\"2020-11-17T16:41:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/\"},\"wordCount\":338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO94935&sd=2020-11-17\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/\",\"name\":\"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO94935&sd=2020-11-17\",\"datePublished\":\"2020-11-17T16:41:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO94935&sd=2020-11-17\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO94935&sd=2020-11-17\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/","og_locale":"en_US","og_type":"article","og_title":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Nov. 17, 2020 \/PRNewswire\/ — Immunovia\u00a0AB (publ) (“Immunovia”) announced today that Immunovia’s Chief Executive Officer, Patrik Dahlen, has acquired Immunovia 15,000 shares for 2.5 MSEK on the open market and his total holding is now 45,000 shares. For more information, please contact: Julie Silber, Director of Investor Relations, Immunovia Email:\u00a0julie.silber@immunovia.com Tel: +46 7 93 486\u00a0277 The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET on November 17, 2020. About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker … Continue reading \"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T16:41:49+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares","datePublished":"2020-11-17T16:41:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/"},"wordCount":338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/","name":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17","datePublished":"2020-11-17T16:41:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO94935&sd=2020-11-17"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chief-executive-officer-patrik-dahlen-buys-immunovia-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383245"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383245\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}